Table 1 Select recent clinical trials of novel targeted therapies in small-cell lung cancer
From: Signal pathways and precision therapy of small-cell lung cancer
Target | Agent | Clinical setting | Phase | NCT numbers | Status | Estimated completion date |
|---|---|---|---|---|---|---|
PARP | Olaparib | Olaparib plus temozolomide | I/II | NCT02446704 | Active | December 2023 |
CHK1 | SRA-737 | SRA-737 in combination with gemcitabine plus cisplatin (versus in combination with low-dose gemcitabine) | I/II | NCT02797977 | Completed | April 2020 |
Aurora A kinase | Alisertib | Paclitaxel with or without alisertib | II | NCT02038647 | Completed | July 10, 2017 |
ATR kinase | M6620 | Topotecan with or without M6620 in relapsed SCLC | II | NCT03896503 | Suspended | September 1, 2023 |
WEE1 | AZD1775 | AZD1775 plus carboplatin as 1 arm of a multiarm phase 2 study of novel combinations in platinum-refractory SCLC | II | NCT02937818 | Active | December 30, 2022 |
Bcl-2/mTOR | Navitoclax and Vistusertib | Relapsed SCLC and other solid tumors | I/II | NCT03366103 | Active | August 31, 2022 |
IDH inhibitors | ivosidenib (AG-120) | solid tumors | I | NCT02073994 | Active | June 2022 |
DLL3 | AMG 119 | Relapsed/Refractory Small-Cell Lung Cancer | I | NCT03392064 | Active | January 13, 2026 |
Hedgehog pathway inhibitor | Vismodegib (GDC-0449) | Cisplatin and etoposide in combination with either Hedgehog inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for patients with extensive-stage small-cell lung cancer | II | NCT00887159 | Completed | January 5, 2021 |
LSD1 inhibitor | Bomedemstat (IMG-7289) | Bomedemstat and maintenance immunotherapy for treatment of newly diagnosed extensive-stage small-cell lung cancer | I/II | NCT05191797 | Not yet recruiting | January 15, 2026 |
EZH1/2 | DS-3201b | DS-3201b plus irinotecan in recurrent SCLC | I/II | NCT03879798 | Recruiting | March 2023 |
VEGFR, PDGFR and FGFR | Anlotinib | Anlotinib plus platinum etoposide in first-line of extensive-stage small-cell lung cancer | II | NCT04675697 | Recruiting | January 31, 2021 |
